Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers

Urology

Volumn 49, Issue 3, 1997, Pages 481-486

  Papandreou, Christos N ^a   Bogenrieder, Thomas ^a   Loganzo, Frank ^a   Albino, Anthony P ^a   Nanus, David M ^a,b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID SUBSTITUTION; ARTICLE; EFFECTOR CELL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; GROWTH REGULATION; HUMAN; HUMAN CELL; KIDNEY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED;

EID: 0030964079     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00493-1     Document Type: Article

References (39)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Suzuki Y, and Tamura G: Mutations of the p53 gene in carcinomas of the urinary system. Acta Pathol Jpn 43: 745-750, 1993.
3. Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, and Koshiba K: Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol 150: 1298-1301, 1993.
4. Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, and Koeffler HP: p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 7: 766-770, 1994.
5. Kikuchi Y, Kishi T, Suzuki M, Furusato M, and Aizawa S: Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas. Virchows Arch 424: 229-233, 1994.
6. Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, and Bosman FT: Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 57: 634-637, 1994.
7. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, Zhang G, and Niehans GA: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 86: 1470-1475, 1994.
8. Hartwell LH, and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
9. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, and Pardee AB: Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54: 380-385, 1994.
10. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, et al: Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 84: 2431-2435, 1994.
11. Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, Watanabe H, Sugimura T, and Terada M: Highly frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 203: 1090-1095, 1994.
12. Vidal MJ, Loganzo F, Oliveira AR, Hayward NK, and Albino AP: Mutations and defective expression of the WAF1 p21 tumor-suppressor gene in malignant melanomas. Melanoma Res 5: 243-250, 1995.
13. Harper JW, Adami GR, Wei N, Keyomarsi K, and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
14. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
15. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
16. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
17. Li Y, Jenkins CW, Nichols MA, and Xiong Y: Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9: 2261-2268, 1994.
18. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT, and Honn KV: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11: 1395-1398, 1995.
19. Ebert T, Bander NH, Finstad CL, Ramsawak RD, and Old LJ: Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 50: 5531-5536, 1990.
20. Albino AP, Lloyd KO, Houghton AN, Oettgen HF, and Old LJ: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med 154: 1764-1778, 1981.
21. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH, and Albino AP: Molecular cloning of the human kidney differentiation antigen gploO: human aminopeptidase A. Proc Natl Acad Sci USA 90: 7069-7073, 1993.
22. Tso JY, Sun X-H, Kao T, Reece KS, and Wu R: Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res 13: 2485-2502, 1985.
23. Loganzo F Jr., Nabeya Y, Maslak P, and Albino AP: Stabilization of p53 protein is a critical response of UV radiation in human melanocytes: implications for melanoma development. Mol Cel Diff 2: 23-43, 1994.
24. Papandreou CN, Bogenrieder T, Scher HI, Albino AP, and Nanus DM: Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. Int J Oncol 8: 1237-1241, 1996.
25. Nanus DM, Mentle IR, Motzer RJ, Bander NH, and Albino AP: Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 143: 175-178, 1990.
26. Albino AP, Davis BM, and Nanus DM: Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res 51: 4815-4820, 1991.
27. Murray V: Improved double-stranded DNA sequencing using the linear polymerase chain reaction. Nucleic Acids Res 17: 88-89, 1989.
28. Dicker AP, Volkenandt M, and Albino AP: Mutational analysis of human n-ras genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. Genes Chromosomes Cancer 1: 257-269, 1990.
29. Vogelstein B, and Kinzler KW: The multistep nature of cancer. Trends Genet 9: 138-141, 1993.
30. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, and Koeffler HP: Absence of WAF1 mutations in a variety of human malignancies. Blood 84: 3781-3784, 1994.
31. Li YJ, Laurent-Puig P, Salmon RJ, Thomas G, and Hamelin R: Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. Oncogene 10: 599-601, 1995.
32. Koopmann J, Maintz D, Schild S, Schramm J, Louis DN, Wiestler OD, and von Deimling A: Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. Br J Cancer 72: 1230-1233, 1995.
33. Watanabe H, Fukuchi K, Takagi Y, Tomoyasu S, Tsuruoka N, and Gomi K: Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim Biophys Acta 1263: 275-280, 1995.
34. Suzuki Y, Tamura G, Satodate R, and Fujioka T: Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 83: 233-235, 1992.
35. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM, and Smith JR: Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinog 11: 59-64, 1994.
36. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
37. Presti JC Jr, Reuter VE, Cordon-Cardo C, Motzer RJ, Albino AP, Jhanwar SC, and Nanus DM: Expression of the retinoblastoma gene product in renal tumors. Anticancer Res 16: 549-556, 1996.
38. Cairns P, Tokino K, Eby Y, and Sidransky D: Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 55: 224-227, 1995.
39. Kinoshita H, Yamada H, Ogawa O, Kakehi Y, Osaka M, Nakamura E, Mishina M, Habuchi T, Takahashi R, Sugiyama T, et al: Contribution of chromosome 9p2122 deletion to the progression of human renal cell carcinoma. Jpn J Cancer Res 86: 795-799, 1995.